Nierziekte

Geen verband tussen epimeer vitamine D en vaatstijfheid of cardiovasculaire uitkomsten bij gevorderde CKD

In een prospectieve cohortstudie onder 270 patiënten met gevorderde chronische nierziekte (stadie 5 en 5D) werd onderzocht of circulerende 3-epi-25(OH)D3-niveaus samenhangen met vaatstijfheid en langdurige cardiovasculaire uitkomsten. Na 9,3 jaar volgjaar waren er geen significante verschillen in carotido-femorale pulse wave velocity, augmentatie-index of een samengestelde uitkomst van cardiovasculaire events en mortaliteit tussen de quartielen van 3-epi-25(OH)D3. Deze bevindingen suggereren dat dit specifieke vitamine D-metaboliet geen onafhankelijke voorspeller is van vaatziekte of sterfte in deze patiëntengroep, wat de klinische relevantie van meting ervan beperkt.

Abstract (original)

RATIONALE & OBJECTIVE: 3-epi-25(OH)D3, an epimeric form of 25(OH)D3 generated by C-3 epimerization, declines with advancing chronic kidney disease (CKD), yet its role in vascular health and related outcomes remains largely unknown. We aimed to determine whether circulating 3-epi-25(OH)D3 levels are associated with arterial stiffness and longitudinal cardiovascular (CV) outcomes in advanced CKD (stages 5 and 5D). STUDY DESIGN: A prospective observational study. SETTING & PARTICIPANTS: A total of 270 patients with advanced CKD using the Cambridge Coventry Vascular cohort. EXPOSURE S OR PREDICTOR S: Baseline 3-epi-25(OH)D3 measured by liquid chromatography-tandem mass spectrometry. OUTCOME S: Arterial stiffness was assessed by carotid-femoral pulse wave velocity (PWV) and augmentation index (AIx75). Longitudinal outcomes included a composite of major CV events and all-cause mortality. ANALYTICAL APPROACH: Baseline 3-epi-25(OH)D3 was categorized into quartiles. Associations were assessed using multivariable regression adjusted for age, race, and dialysis status. Kaplan-Meier and Cox models assessed longitudinal outcomes. RESULTS: Among 270 participants, quartiles were Q1 < 0.30 ng/mL (n = 64), Q2: 0.30-0.456 ng/mL (n = 71), Q3: 0.457-0.729 ng/mL (n = 68), and Q4 ≥ 0.73 ng/mL (n = 67). Strata were similar in age (44.9 years), sex, and BMI (all P > 0.05). Race differed by quartile (P < 0.001); 87.4% were White. 24.8% were pre-dialytic, 61.1% treated with hemodialysis, and 14.1% treated with peritoneal dialysis. Arterial stiffness was similar across quartiles (AIx75 ∼20-21%, P = 0.99; PWV: 7.8-8.0 m/s, P = 0.94). 3-epi-25(OH)D3 showed no association with AIx75 or PWV before or after adjustment using multiple regression modeling. Over 9.3 years, 115 composite events occurred (97 CV events, 18 deaths). Kaplan-Meier analysis did not discriminate risk across 3-epi-25(OH)D3 quartiles for the composite outcome (log-rank P = 0.23), and adjusted Cox models showed no association. LIMITATIONS: Observational design with possible residual confounding. CONCLUSION: In advanced CKD, 3-epi-25(OH)D3 showed no independent association with arterial stiffness or CV events and mortality. Further studies are needed to determine the role of epimeric vitamin D in patients with CKD.

Dit artikel is een samenvatting van een publicatie in Kidney medicine. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.

Lees het volledige artikel

DOI: 10.1016/j.xkme.2026.101519

Wilt u op de hoogte blijven?

Gratis: de maandelijkse nieuwsbrief met het nieuwsoverzicht, en de site afgestemd op uw vakgebied.

Schrijf u nu in